WEHI-345

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameWEHI-345
Drug Alias NameRIPK2 inhibitor (Walter and Eliza Hall Institute of Medical Research)WEHI-345
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase RIPK2 inhibitors
TargetsSerine/threonine-protein kinase RIPK2
Therapy Area/IndicationsMultiple Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia and New Zealand
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesWalter And Eliza Hall Institute Of Medical Research
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesWalter And Eliza Hall Institute Of Medical Research
Active IndicationsN/A
Inactive IndicationsMultiple Sclerosis

Other Information

ATC CodeN/A
Related LinksN/A